Inroads in the Therapy of Indolent Lymphomas: Exploiting Biological Insights

References

• The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute-sponsored study of classifications of non-Hodgkin's lymphomas. Cancer 1982; 49: 2112–2135
   PubMed Web of Science ®Google Scholar
• Stansfeld A., Diebold J., Kapanci Y., et al. Updated Kiel classification for lymphomas. Lancet 1988; 1: 292–293
   PubMed Web of Science ®Google Scholar
• Harris N. L., Jaffe E. S., Stein H., et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A. Classification of lymphoid neoplasms. Blood 1994; 84: 1359–1360
   PubMed Web of Science ®Google Scholar
• Fisher R. I., Grogan T. M., Dahlberg S., et al. Clinical behavior of 2,168 patients treated on Southwest Oncology Group protocols and reclassified according to the R.E.A.L classification. Ann Oncol 1996; 7(Suppl 3)3, (abstract)
   Google Scholar
• Coiffier B., Anderson J., Armitage J., et al. Clinical prognostic factors are stronger predictors of outcome in non-Hodgkin's lymphoma then pathologic subtype. Blood 1996; 88: 293a, (Suppl) (abstract)
   Google Scholar
• Hockenbery D., Nunez G., Milliman C., et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334–336
   PubMed Web of Science ®Google Scholar
• Korsmeyer S. J. bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992; 80: 879–886
   PubMed Web of Science ®Google Scholar
• Weiss L. M., Warnke R. A., Sklar I., Cleary M. L. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl I Med 1987; 314: 1185–1189
   Google Scholar
• Miyashita T., Reed J. C. Bcl-2 oncoprotein blocks chemotherapyinduced apoptosis in a human leukemia cell line. Blood 1993; 81: 151–157
   PubMed Web of Science ®Google Scholar
• Miyashita T., Reed I. C. bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 1992; 52: 407–5411
   Google Scholar
• Lee M. S. Molecular aspects of chromosomal translocation t(14; 18). Semin Hematol 1993; 30: 297–305
   PubMed Web of Science ®Google Scholar
• Lambrechts A. C., Hupkes P. E., Dorssers L. C. J., et al. Translocation (14;18)-positive cells are present in the circulation of the majority of patients with localized (stage I and II) follicular non-Hodgkin's lymphoma. Blood 1993; 82: 2510–2516
   PubMed Web of Science ®Google Scholar
• Berinstein N. L., Reis M. D., Ngan B. Y., et al. Detection of occult lymphoma in the peripheral blood and bone marrow of patients with untreated early-stage and advanced-stage follicular lymphoma. J Clin Oncol 1993; 11: 1344–1352
   PubMed Web of Science ®Google Scholar
• Cabanillas F., Lee M. S., McLaughlin P., et al. Polymerase chain reaction: an effective way of monitoring response in follicular lymphomas. Proc Am Soc Clin Oncol 1993; 12: 365, (abstract)
   Google Scholar
• Gribben J. G., Freedman A. S., Woo S. D., et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 1991; 78: 3275–3280
   PubMed Web of Science ®Google Scholar
• Limpens J., de Jong D., van Krieken J. HJM. bcl-2/JH rearrangements in benign lymphoid tissues with follicular hyperplasia. Oncogene 1991; 6: 2271–2276
   PubMed Web of Science ®Google Scholar
• Limpens J., Stad R., Vos C., et al. Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood 1995; 85: 2528–2536
   PubMed Web of Science ®Google Scholar
• Price C. G. A., Meerabux J., Murtagh S., et al. The significance of circulating cells carrying t(14;18) in long remission from follicular lymphoma. J Clin Oncol 1991; 9: 1527–1532
   PubMed Web of Science ®Google Scholar
• Lambrechts A. C., Hupkes P. E., Dorssers L. C. J., et al. Clinical significance of t(14;18)-positive cells in the circulation of patients with stage III or IV follicular non-Hodgkin's lymphoma during first remission. J Clin Oncol 1994; 12: 1541–1546
   PubMed Web of Science ®Google Scholar
• Gribben J. G., Freedman A. S., Neuberg D., et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991; 325: 1525–1533
   PubMed Web of Science ®Google Scholar
• Johnson P. W. M., Price C. G. A., Smith T., et al. Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma. J Clin Oncol 1994; 12: 798–805
   PubMed Web of Science ®Google Scholar
• Gribben J. G., Neuberg D., Freedman A. S., et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993; 81: 3449–3457
   PubMed Web of Science ®Google Scholar
• McLaughlin P., Hagemeister F. B., Swan F., et al. Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: High remission rates and reversion to negative of peripheral blood bcl-2 rearrangement. Ann Oncol 1994; 5(Suppl 2)S73–77
   PubMedGoogle Scholar
• McLaughlin P., Cabanillas F., Younes A., et al. Stage IV low grade lymphoma: Randomized trial of two innovative regimens, with monitoring of bcl-2 by PCR. Ann Oncol 1996; 7(Suppl 3)34, (abstract)
   Google Scholar
• Jain V., Ogden J., Cooper, et al. Achievement of molecular complete remissions in patients with bulky follicular lymphomas using alternating cycles fludarabine. mitoxantrone, dexamethasone with CHOP chemotherapy. Blood 1996; 88: 452a, (Suppl) (abstract)
   Google Scholar
• Cabanillas F., Grillo-López A. J., McLaughlin P., et al. Anti-CD20 antibody, IDEC-C2B8: Clearance of bcl-21(14;18) positive cells from peripheral blood and bone marrow in patients with relapsed low-grade or follicular lymphoma. Blood 1996; 88: 91a, (Suppl) (abstract)
   Web of Science ®Google Scholar
• Czuczman M., Grillo-López A. J., White C. A., et al. IDEC-C2B8/CHOP chemoimmunotherapy in patients with low-grade lymphoma: Clinical and BCL-2 final results. Blood 1996; 88: 453a, (Suppl) (abstract)
   Google Scholar
• Cabanillas F., Lee M. S., McLaughlin P., et al. Early achievement of molecular complete remission assayed by PCR predicts failure-free survival in low grade follicular lymphomas. Blood 1995; 86: 604a, (Suppl) (abstract)
   Google Scholar
• Gospodarowicz M. K., Bush R. S., Brown T. C., et al. Prognostic factors in nodular lymphomas: A multivariate analysis based on the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys 1984; 10: 489–497
   PubMed Web of Science ®Google Scholar
• Paryani S. B., Hoppe R. T., Cox R. S., et al. Analysis of non-Hodg-kin's lymphomas with nodular and favorable histologies, stages I and II. Cancer 1983; 52: 2300–2307
   PubMed Web of Science ®Google Scholar
• McLaughlin P., Fuller L. M., Velasquez W. S., et al. Stage MI follicular lymphoma. Treatment results for 76 patients. Cancer 1986; 58: 1596–1602
   PubMed Web of Science ®Google Scholar
• Horning S. J. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993; 20: 75–88
   PubMed Web of Science ®Google Scholar
• Romaguera J. E., McLaughlin P., North L., et al. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: A risk model. J Clin Oncol 1991; 9: 762–769
   PubMed Web of Science ®Google Scholar
• Soubeyran P., Eghbali H., Bonichon F., et al. Low-grade follicular lymphomas: Analysis of prognosis in a series of 281 patients. Eur J Cancer 1991; 27: 1606–1613
   PubMed Web of Science ®Google Scholar
• Gallagher C. J., Gregory W. M., Jones A. E., et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 1986; 4: 1470–1480
   PubMed Web of Science ®Google Scholar
• Lopez-Guillermo A., Montserrat E., Bosch F., et al. Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 1994; 12: 1343–1348
   PubMed Web of Science ®Google Scholar
• The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Litam P., Swan F., Cabanillas F., et al. Prognostic value of serum P-2 microglobulin in low-grade lymphoma. Ann Intern Med 1991; 114: 855–860
   PubMed Web of Science ®Google Scholar
• Velasquez W. S., Jagannath S., Tucker S. L., et al. Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-year survival data. Blood 1989; 74: 551–557
   PubMed Web of Science ®Google Scholar
• Shipp M. A., Harrington D. P., Klatt M. M., et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med 1986; 104: 757–765
   PubMed Web of Science ®Google Scholar
• Coiffier B., Gisselbrecht C., Vose J. M., et al. Prognostic factors in aggressive malignant lymphomas: Description and validation of a prognostic index that could identify patients requiring a more intensive therapy. J Clin Oncol 1991; 9: 211–219
   PubMed Web of Science ®Google Scholar
• Mariano M. T., Moretti L., Donelli A., et al. Bcl-2 gene expression in hematopoietic cell differentiation. Blood 1992; 80: 768–775
   PubMed Web of Science ®Google Scholar
• Harris N. L. Low-grade B-cell lymphoma of mucosa-associated lymphoid tissue and monocytoid B-cell lymphoma. Arch Pathol Lab Med 1993; 117: 771–775
   PubMed Web of Science ®Google Scholar
• Fisher R. I., Dahlberg S., Bharat N., et al. A clinical analysis of two indolent lymphoma entities: Mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): A Southwest Oncology Group Study. Blood 1995; 85: 1075–1082
   PubMed Web of Science ®Google Scholar
• Wotherspoon A. C., Doglioni C., Diss T. C., et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993; 342: 575–577
   PubMed Web of Science ®Google Scholar
• Majlis A., Pugh W., Rodriguez M. A., Cabanillas F. Three histological variants of mantle cell lymphoma exhibit striking heterogeneity in clinical behavior and biological features. Blood 1993; 82: 338a, (Suppl) (abstract)
   Google Scholar
• Coiffier B. How should prognostic factors influence therapy in follicular lymphomas?. Ann Oncol 1991; 2: 619–620
   PubMed Web of Science ®Google Scholar
• MacManus M., Hoppe R. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996; 14: 1282–1290
   PubMed Web of Science ®Google Scholar
• Finke J., Slanina J., Lange W., Dolken G. Persistence of circulating t(14;18)-positive cells in long-term remission after radiation therapy for localized-stage follicular lymphoma. J Clin Oncol 1993; 11: 1668–1673
   PubMed Web of Science ®Google Scholar
• Seymour J. E., McLaughlin P., Fuller L. M., et al. High rate of prolonged remissions following combined modality therapy for patients with localized low-grade lymphoma. Ann Oncol 1996; 7: 157–163
   PubMed Web of Science ®Google Scholar
• Paryani S. B., Hoppe R. T., Cox R. S., et al. The role of radiation therapy in the management of stage III follicular lymphomas. J Clin Oncol 1984; 2: 841–848
   PubMed Web of Science ®Google Scholar
• McLaughlin P., Fuller L. M., Velasquez W. S., et al. Stage III follicular lymphoma: Durable remissions with a combined chemotherapy-radiotherapy regimen. J Clin Oncol 1987; 5: 867–874
   PubMed Web of Science ®Google Scholar
• Jacobs J. P., Murray K. J., Schultz C. J., et al. Central lymphatic irradiation for stage III nodular malignant lymphoma: Long-term results. J Clin Oncol 1993; 11: 233–238
   PubMed Web of Science ®Google Scholar
• Anderson T., Bender R. A., Fisher R. I., et al. Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term follow-up. Cancer Treat Rep 1977; 61: 1057–1066
   PubMedGoogle Scholar
• Longo D. L., Young R. C., Hubbard S. M., et al. Prolonged initial remission in patients with nodular mixed lymphoma. Ann Intern Med 1984; 100: 651–656
   PubMed Web of Science ®Google Scholar
• Glick J. H., Barnes J. M., Ezdinli E. Z., et al. Nodular mixed lymphoma: Results of a randomized trial failing to confirm prolonged disease-free survival with COPP chemotherapy. Blood 1981; 58: 920–925
   PubMed Web of Science ®Google Scholar
• Horning S. J., Rosenberg S. A. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984; 311: 1471–1475
   PubMed Web of Science ®Google Scholar
• Peterson B. A., Anderson J. R., Frizzera G., et al. Combination chemotherapy prolongs survival in follicular mixed lymphoma. Proc Am Soc Clin Oncol 1990; 9: 259, (abstract)
   Google Scholar
• Leiby J., Snider K., Kraut E., et al. Phase II trial of 9-P-D-arabino-syl-2-fluoroadenine-5′-monophosphate in non-Hodgkin's lymphoma: Prospective comparison of response with deoxycytidine kinase activity. Cancer Res 1987; 47: 2719–2722
   PubMed Web of Science ®Google Scholar
• Hochster H., Kyungmann K., Green M., et al. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: Results of an Eastern Cooperative Oncology Group study. J Clin Oncol 1992; 10: 28–32
   PubMed Web of Science ®Google Scholar
• Redman J., Cabanillas F., Velasquez W., et al. Phase II trial of fludarabine phosphate in lymphoma: An effective new agent for low-grade lymphoma. J Clin Oncol 1992; 10: 790–794
   PubMed Web of Science ®Google Scholar
• Glick J. H., McFadden E., Costello W., et al. Nodular histiocytic lymphoma: Factors influencing prognosis and implications for aggressive chemotherapy. Cancer 1982; 49: 840–845
   PubMed Web of Science ®Google Scholar
• Bartlett N. L., Rizeq M., Dorfman R. F., et al. Follicular large-cell lymphoma: intermediate or low grade?. J Clin Oncol 1994; 12: 1349–1357
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., McLaughlin P., Fuller L. M., et al. Follicular large cell lymphoma: Analysis and prognostic factors in 62 patients. J Clin Oncol 1984; 2: 811–819
   PubMed Web of Science ®Google Scholar
• Anderson J. R., Vose J. M., Bierman P. J., et al. Clinical features and prognosis of follicular large-cell lymphoma: A report from the Nebraska Lymphoma Study Group. J Clin Oncol 1993; 11: 218–224
   PubMed Web of Science ®Google Scholar
• Gilewski T. A., Richards J. M. Biologic response modifiers in non-Hodgkin's lymphomas. Semin Oncol 1990; 17: 74–87
   PubMed Web of Science ®Google Scholar
• Smalley R. V., Andersen J. W., Hawkins M. I., et al. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med 1992; 327: 1336–1341
   PubMed Web of Science ®Google Scholar
• Price C. G. A., Rohatiner A. Z. S., Steward W., et al. Interferon-ct2b in the treatment of follicular lymphoma: Preliminary results of a trial in progress. Ann Oncol 1991; 2(Suppl 2)141–145
   PubMed Web of Science ®Google Scholar
• McLaughlin P., Cabanillas F., Hagemeister F. B., et al. CHOP-Bleo plus interferon for stage IV low grade lymphoma. Ann Oncol 1993; 4: 205–211
   PubMed Web of Science ®Google Scholar
• Hagenbeek A., Carde P., Somers R., et al. Interferon-alfa-2a vs control as maintenance therapy for low grade non-Hodgkin's lymphoma: results from a prospective randomized clinical trial. Proc Am Soc Clin Oncol 1995; 14: 386, (abstract)
   Google Scholar
• Solal-Celigny P., Lepage E., Brousse N., et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N Engl J Med 1993; 329: 1608–1614
   PubMed Web of Science ®Google Scholar
• Peterson B. A., Petroni G., Oken M. M., et al. Cylophosphamide versus cyclophosphamide plus interferon alfa-2b in follicular low-grade lymphomas: A preliminary report of an intergroup trial (CALGB 8691 and EST 7486). Proc Am Soc Clin Oncol 1993; 12: 366, (abstract)
   Google Scholar
• Unterhalt M., Hermann R., Nahler M., et al. Significant prolongation of disease-free survival in advanced low grade non-Hodgkin's lymphomas by interferon alpha maintenance. Blood 1995; 86: 439a, (Suppl) (abstract)
   Google Scholar
• Solal-Celigny P., Lepage E., Broussen, et al. A doxorubicin containing regimen with or without interferon alpha 2b in advanced follicular lymphomas. Final analysis of survival, toxicity and quality of life of the GELF86 trial. Blood 1996; 88: 453a, (Suppl) (abstract)
   Google Scholar
• McLaughlin P. The role of interferon in the therapy of malignant lymphoma. Biomed Pharmacother 1996; 50: 140–148
   PubMed Web of Science ®Google Scholar
• Cheson B. D. New antimetabolites in the treatment of human malignancies. Semin Oncol 1992; 19: 695–706
   PubMed Web of Science ®Google Scholar
• Robertson L., Chubb S., Meyn R., et al. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-de-oxyadenosine and 9-β-D-arabinosyl-2-fluoroadenine. Blood 1993; 81: 143–150
   PubMed Web of Science ®Google Scholar
• Frankfurt O., Byrnes J., Seckinger D., et al. Apoptosis (programmed cell death) and the evaluation of chemosensitivity in chronic lymphocytic leukemia and lymphoma. Oncol Res 1993; 5: 37–42
   PubMed Web of Science ®Google Scholar
• Zinzani P., Lauria F., Rondelli D., et al. Fludarabine: An active agent in the treatment of previously-treated and untreated low grade non-Hodgkin's lymphoma. Ann Oncol 1993; 4: 575–578
   PubMed Web of Science ®Google Scholar
• Dumontet C., Bastion Y., Bazin M., et al. Fludarabine therapy in low-grade non-Hodgkin's lymphoma: Results of the Lyon-Sud experience. Proceedings of the 5th International Conference on Malignant Lymphoma, LuganoSwitzerland, 1993, 97, (abstract)
   Google Scholar
• Dohner H., Fischer K., Thaler J., et al. Fludarabine phosphate in the treatment of relapsed or refractory low grade non-Hodgkin's lymphomas. Proceedings of the 5th International Conference on Malignant Lymphoma, LuganoSwitzerland, 1993, 151, (abstract)
   Google Scholar
• Hiddemann W., Unterhalt M., Pott C., et al. Fludarabine singleagent therapy for relapsed low-grade non-Hodgkin's lymphomas: A phase II study of the German low-grade non-Hodgkin's lymphoma study group. Semin Oncol 1993; 20(Suppl 7)28–31
   PubMedGoogle Scholar
• Pigaditou A., Rohatiner A., Whelan J. S., et al. Fludarabine in lowgrade lymphoma. Semin Oncol 1993; 20(Suppl 7)24–27
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P. H., Brice P., Brousse N., et al. Phase-II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma. A multicenter study by the “Groupe d'Etude des Lymphomes de PAdulte.”. J Clin Oncol 1996; 14: 514–519
   PubMed Web of Science ®Google Scholar
• Kay A. C., Saven A., Carrera C. J., et al. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol 1992; 10: 371–377
   PubMed Web of Science ®Google Scholar
• Hickish T., Serafinowski P., Cunningham D., et al. 2′-Chlorodeoxyadenosine: Evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies. Br J Cancer 1993; 67: 139–143
   PubMed Web of Science ®Google Scholar
• Emanuele S., Saven M., Kosty D., et al. 2-Chlorodeoxyadenosine activity in patients with untreated low-grade lymphoma. Proc Am Soc Clin Oncol 1994; 13: 306, (abstract)
   Google Scholar
• Canfield V., Vose J., Nichols C. Phase II trial of 2-chloro-deoxy-adenosine in patients with untreated low grade non-Hodgkin's lymphoma. Blood 1994; 84: 168a, (Suppl) (abstract)
   Web of Science ®Google Scholar
• Liliemark J., Hagberg H., Cavallin-Ståhl E., et al. Cladribine for early low-grade non-Hodgkin's lymphoma. Blood 1994; 84: 168a, (Suppl) (abstract)
   Web of Science ®Google Scholar
• Taylor K., Bunce I., Eliadis P., et al. Short infusional 2-chloro-deoxyadenosine—Effective therapy in relapsed or poor risk de novo low grade non-Hodgkin's lymphoma. Blood 1994; 84: 168a, (Suppl) (abstract)
   Web of Science ®Google Scholar
• Hoffman M., Tallman M., Janson D., et al. 2-chlorodeoxyadenosine is an active salvage therapy in indolent non-Hodgkin's lymphoma. Blood 1993; 82: 142a, (Suppl) (abstract)
   Web of Science ®Google Scholar
• Monfardini S., Sorio R., Cavalli F., et al. Tolerance of low dose deoxycoformycin in malignant lymphomas. Proc Am Assoc Cancer Res 1990; 31: 194, (abstract)
   Google Scholar
• Duggan D. B., Anderson J. R., Dillman R., et al. 2′ Deoxycoformycin (Pentostatin) for refractory non-Hodgkin's lymphoma: A CALGB phase II study. Med Ped Oncol 1990; 18: 203–206
   PubMedGoogle Scholar
• Cummings F. J., Kim K., Neiman R. S., et al. Phase II trial of Pentostatin in refractory lymphomas and cutaneous T-cell disease. J Clin Oncol 1991; 9: 565–571
   PubMed Web of Science ®Google Scholar
• Saven A., Lee T., Kosty M., Piro L. Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma. J Clin Oncol 1996; 14: 2139–2144
   PubMed Web of Science ®Google Scholar
• McLaughlin P., Hagemeister F. B., Swan F., et al. Phase I study of the combination of fludarabine, mitoxantrone, and dexametha-sone in low grade lymphoma. J Clin Oncol 1994; 12: 575–579
   PubMed Web of Science ®Google Scholar
• McLaughlin P., Hagemeister F. B., Sarris A., et al. Fludarabine, mitoxantrone, and dexamethasone for recurrent low grade lymphoma: A phase II trial. J Clin Oncol 1996; 14: 1262–1268
   PubMed Web of Science ®Google Scholar
• Zinzani P. L., Bendandi M., Tura S. FMP regimen (fludarabine, mitoxantrone, prednisone) as therapy in recurrent low-grade non-Hodgkin's lymphoma. Eur J Haematol 1995; 55: 262–266
   PubMed Web of Science ®Google Scholar
• Hochster H., Oken M., Bennett J., et al. Efficacy of cyclophosphamide and fludarabine as first line therapy of low-grade non-Hodgkin's lymphoma-ECOG 1491. Blood 1994; 84: 383a, (Suppl) (abstract)
   Web of Science ®Google Scholar
• Gribben J. G., Neuberg D., Barber M., et al. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow. Blood 1994; 83: 3800–3807
   PubMed Web of Science ®Google Scholar
• Grossbard M. L., Press O. W., Appelbaum F. R., et al. Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 1992; 80: 863–878
   PubMed Web of Science ®Google Scholar
• Calabretta B., Skorski T., Szczylik C., et al. Prospects for gene-directed therapy with antisense oligodeoxynucleotides. Cancer Treat Rev 1993; 19: 169–179
   PubMed Web of Science ®Google Scholar
• Miller R. A., Maloney D. G., Warnke R., et al. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 1982; 306: 517–522
   PubMed Web of Science ®Google Scholar
• Miller R. A., Hart S., Samoszuk M., et al. Shared idiotypes expressed by human B-cell lymphomas. N Engl J Med 1989; 321: 851–857
   PubMed Web of Science ®Google Scholar
• Clendennin N. J., Nethersell A. B. W., Scott J. E., et al. Early safety and efficacy results using Campath-IH, a humanized anti-lymphocyte monoclonal antibody, in non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Proc Am Soc Clin Oncol 1993; 12: 378, (abstract)
   Google Scholar
• Maloney D. G., Liles T. M., Czerwinski D. K., et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457–2466
   PubMed Web of Science ®Google Scholar
• McLaughlin P., Cabanillas F., Grillo-López A. J., et al. IDEC-C2B8 anti-CD20 antibody: Final report on a phase III pivotal trial in patients with relapsed low-grade, or follicular lymphoma. Blood 1996; 88: 90a, (Suppl) (abstract)
   Google Scholar
• Vitetta E. S., Uhr J. W., Thorpe P. E. Immunotoxin therapy. Cancer: Principles and Practices of Oncology 4th ed., V. T. DeVita, Jr, S. Hellman, S. A. Rosenberg. Lippincott, Philadelphia 1993; 2624–2636
   Google Scholar
• Grossbard M. L., Lambert J. M., Goldmacher V. S., et al. Anti-B4 blocked ricin: A phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J Clin Oncol 1993; 11: 726–737
   PubMed Web of Science ®Google Scholar
• Press O. W., Eary J. F., Appelbaum F. R., et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993; 329: 1219–1224
   PubMed Web of Science ®Google Scholar
• Kaminski M. S., Zasadny K. R., Francis I. R., et al. Radioimmunother-apy of B-cell lymphoma with [131I] anti-Bl (anti-CD20) antibody. N Engl J Med 1993; 329: 459–465
   PubMed Web of Science ®Google Scholar
• Reed J. C., Kitada S., Takayama T. M. Regulation of chemoresis-tance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol 1994; 5(Suppl 1)S61–65
   PubMedGoogle Scholar
• Webb A., Cunningham D., Cotter F., et al. Phase I bcl-2 antisense trial: Preliminary results. Ann Oncol 1996; 7(Suppl 3)32, (abstract)
   Google Scholar
• The non-Hodgkin's Lymphoma Classification Report. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997; 89: 3909–3918
   PubMed Web of Science ®Google Scholar
• Pittaluga S., Bijnens L., Teodorovic I., et al. Clinical analysis of 670 cases in two trials of the European Organization for the Research and Treatment of Cancer lymphoma cooperative group subtyped according to the revised European-American classification of lymphoid neoplasms: A comparison with the Working Formulation. Blood 1996; 87: 4358–4367
   PubMed Web of Science ®Google Scholar
• Armitage J. O., Weisenburger D. D., et al. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. J Clin Oncol 1998; 16: 2780–2795
   PubMed Web of Science ®Google Scholar